ArticleFuture oncology (London, England)2017
End points and statistical considerations in immuno-oncology trials: impact on multiple myeloma.
Article in Future oncology (London, England), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Efficacy and safety of anticancer drug combinations: a meta-analysis of randomized trials with a focus on immunotherapeutics and gene-targeted compounds.Oncoimmunology · 2020Pooled it
- A Comparison of Response Patterns for Progression-Free Survival and Overall Survival Following Treatment for Cancer With PD-1 Inhibitors: A Meta-analysis of Correlation and Differences in Effect Sizes.JAMA network open · 2018Pooled it
- Ten challenges and opportunities in computational immuno-oncology.Journal for immunotherapy of cancer · 2024Review
- Futility monitoring for randomized clinical trials with non-proportional hazards: An optimal conditional power approach.Clinical trials (London, England) · 2023Article
- Review
- Statistical considerations in long-term efficacy evaluation of anti-cancer therapies.Frontiers in pharmacology · 2023Review
- Pembrolizumab plus lenalidomide and dexamethasone in treatment-naive multiple myeloma (KEYNOTE-185): subgroup analysis in Japanese patients.International journal of hematology · 2020Article
- Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective.Journal for immunotherapy of cancer · 2020Article
- ImmunoPET in Multiple Myeloma-What? So What? Now What?Cancers · 2020Article
- Methods for Accommodating Nonproportional Hazards in Clinical Trials: Ready for the Primary Analysis?Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2019Article
- Comparison of Long-term Survival Benefits in Trials of Immune Checkpoint Inhibitor vs Non-Immune Checkpoint Inhibitor Anticancer Agents Using ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale.JAMA network open · 2019Article
- Challenges and shifting paradigms in clinical trials in oncology: the case for immunological and targeted therapies.Ecancermedicalscience · 2019Review
- Mechanisms of Action and Clinical Development of Elotuzumab.Clinical and translational science · 2018Review
- Cancer treatment in the last 6 months of life: when inaction can outperform action.Ecancermedicalscience · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Unlike conventional cancer treatment, immuno-oncology therapies are commonly associated with delayed clinical benefit and durable responses, as seen with immuno-oncology therapies for multiple myeloma (MM). Therefore, a longer-term approach to immuno-oncology data assessment is required. Appropriate study designs, end points and statistical methods are essential for evaluating immuno-oncology therapies to assess treatment outcomes, and may better accommodate immuno-oncology clinical trial data. In addition to conventional end points including median progression-free survival (PFS) and overall survival (OS), end points such as hazard ratios for PFS and OS over time, PFS and OS landmark analyses beyond the median, and immune-response end points might provide better indications of the efficacy of immuno-oncology therapies. Long-term data with these agents will allow better prediction of outcomes in MM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.